| The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and PatientsTherapeutic Insight from the KRASG12C … J Hallin, LD Engstrom, L Hargis, A Calinisan, R Aranda, DM Briere, ... Cancer discovery 10 (1), 54-71, 2020 | 553 | 2020 |
| Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors … V Ludovini, F Bianconi, L Pistola, R Chiari, V Minotti, R Colella, D Giuffrida, ... Journal of thoracic oncology 6 (4), 707-715, 2011 | 180 | 2011 |
| The KRAS (G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020; 10: 54–71. doi … J Hallin, LD Engstrom, L Hargis, A Calinisan, R Aranda, DM Briere, ... Nat Can 1 (1), 25-7, 2020 | 142 | 2020 |
| Multiclass HCV resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies VC Di Maio, V Cento, I Lenci, M Aragri, P Rossi, S Barbaliscia, M Melis, ... Liver international 37 (4), 514-528, 2017 | 87 | 2017 |
| Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell … V Ludovini, I Floriani, L Pistola, V Minotti, M Meacci, R Chiari, ... Journal of thoracic oncology 6 (12), 2018-2026, 2011 | 59 | 2011 |
| Computational model of EGFR and IGF1R pathways in lung cancer: a systems biology approach for translational oncology F Bianconi, E Baldelli, V Ludovini, L Crino, A Flacco, P Valigi Biotechnology advances 30 (1), 142-153, 2012 | 50 | 2012 |
| Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations V Ludovini, F Bianconi, L Pistola, V Minotti, R Chiari, R Colella, ... Cancer chemotherapy and pharmacology 69 (5), 1289-1299, 2012 | 48 | 2012 |
| Reverse phase protein microarrays E Baldelli, V Calvert, A Hodge, A VanMeter, EF Petricoin, M Pierobon Molecular profiling, 149-169, 2017 | 40 | 2017 |
| Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer … E Baldelli, EB Haura, L Crinò, DW Cress, V Ludovini, MB Schabath, ... PROTEOMICS–Clinical Applications 9 (9-10), 928-937, 2015 | 31 | 2015 |
| The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cellsc-MYC Drives Nab-Paclitaxel Resistance in Pancreatic Cancer E Parasido, GS Avetian, A Naeem, G Graham, M Pishvaian, E Glasgow, ... Molecular Cancer Research 17 (9), 1815-1827, 2019 | 30 | 2019 |
| Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy MI Sereni, E Baldelli, G Gambara, J Deng, L Zanotti, E Bandiera, ... Proteomics 15 (2-3), 365-373, 2015 | 30 | 2015 |
| Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors E Baldelli, G Bellezza, EB Haura, L Crinó, WD Cress, J Deng, V Ludovini, ... Oncotarget 6 (32), 32368, 2015 | 27 | 2015 |
| Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients V Ludovini, A Flacco, F Bianconi, M Ragusa, J Vannucci, G Bellezza, ... Cancer chemotherapy and pharmacology 71 (3), 671-680, 2013 | 22 | 2013 |
| A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray E Pin, S Stratton, C Belluco, L Liotta, R Nagle, KA Hodge, J Deng, T Dong, ... Molecular oncology 10 (10), 1585-1594, 2016 | 21 | 2016 |
| Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology F Bianconi, E Baldelli, V Luovini, EF Petricoin, L Crinò, P Valigi BMC systems biology 9 (1), 1-18, 2015 | 16 | 2015 |
| HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels VC Di Maio, V Cento, D Di Paolo, M Aragri, F De Leonardis, ... Journal of Antimicrobial Chemotherapy 71 (3), 739-750, 2016 | 14 | 2016 |
| The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer JN Diehl, JE Klomp, KR Snare, PS Hibshman, DR Blake, ZD Kaiser, ... Journal of Biological Chemistry 297 (5), 2021 | 8 | 2021 |
| Kinase-driven metabolic signalling as a predictor of response to carboplatin–paclitaxel adjuvant treatment in advanced ovarian cancers MI Sereni, E Baldelli, G Gambara, A Ravaggi, KA Hodge, DS Alberts, ... British journal of cancer 117 (4), 494-502, 2017 | 8 | 2017 |
| Robustness of complex feedback systems: application to oncological biochemical networks F Bianconi, E Baldelli, V Ludovini, L Crinò, K Perruccio, P Valigi International Journal of Control 86 (7), 1304-1321, 2013 | 7 | 2013 |
| Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN M Codrich, E Dalla, C Mio, G Antoniali, MC Malfatti, S Marzinotto, ... Journal of Experimental & Clinical Cancer Research 40 (1), 1-17, 2021 | 5 | 2021 |
